220 related articles for article (PubMed ID: 27678443)
21. Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients.
Yadav R; Liu Y; Kwok S; Hama S; France M; Eatough R; Pemberton P; Schofield J; Siahmansur TJ; Malik R; Ammori BA; Issa B; Younis N; Donn R; Stevens A; Durrington P; Soran H
J Am Heart Assoc; 2015 Sep; 4(9):e001508. PubMed ID: 26374297
[TBL] [Abstract][Full Text] [Related]
22. Relations of change in plasma levels of LDL-C, non-HDL-C and apoB with risk reduction from statin therapy: a meta-analysis of randomized trials.
Thanassoulis G; Williams K; Ye K; Brook R; Couture P; Lawler PR; de Graaf J; Furberg CD; Sniderman A
J Am Heart Assoc; 2014 Apr; 3(2):e000759. PubMed ID: 24732920
[TBL] [Abstract][Full Text] [Related]
23. Concordance between plasma apolipoprotein B levels and cholesterol indices among patients receiving statins and nonstatin treatment: Post-hoc analyses from the U.K. InPractice study.
Idris I; Tate H; Ahmad A; McCormack T
J Clin Lipidol; 2011; 5(4):316-23. PubMed ID: 21784378
[TBL] [Abstract][Full Text] [Related]
24. The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk.
Walldius G; Jungner I; Aastveit AH; Holme I; Furberg CD; Sniderman AD
Clin Chem Lab Med; 2004; 42(12):1355-63. PubMed ID: 15576296
[TBL] [Abstract][Full Text] [Related]
25. Apolipoprotein B vs non-high-density lipoprotein cholesterol: Association with endothelial hemostatic markers and carotid intima-media thickness.
Karasek D; Vaverkova H; Cibickova L; Gajdova J; Kubickova V
J Clin Lipidol; 2017; 11(2):442-449. PubMed ID: 28502501
[TBL] [Abstract][Full Text] [Related]
26. Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients.
Johannesen CDL; Mortensen MB; Langsted A; Nordestgaard BG
J Am Coll Cardiol; 2021 Mar; 77(11):1439-1450. PubMed ID: 33736827
[TBL] [Abstract][Full Text] [Related]
27. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels.
Querton L; Buysschaert M; Hermans MP
J Clin Lipidol; 2012; 6(5):434-42. PubMed ID: 23009779
[TBL] [Abstract][Full Text] [Related]
28. Discordance between lipid markers used for predicting cardiovascular risk in patients with type 2 diabetes.
Modi KD; Chandwani R; Ahmed I; Kumar KV
Diabetes Metab Syndr; 2016; 10(1 Suppl 1):S99-S102. PubMed ID: 26589777
[TBL] [Abstract][Full Text] [Related]
29. Novel and traditional lipid profiles in Metabolic Syndrome reveal a high atherogenicity.
Paredes S; Fonseca L; Ribeiro L; Ramos H; Oliveira JC; Palma I
Sci Rep; 2019 Aug; 9(1):11792. PubMed ID: 31409878
[TBL] [Abstract][Full Text] [Related]
30. The graded relationship between glucose tolerance status in pregnancy and postpartum levels of low-density-lipoprotein cholesterol and apolipoprotein B in young women: implications for future cardiovascular risk.
Retnakaran R; Qi Y; Connelly PW; Sermer M; Hanley AJ; Zinman B
J Clin Endocrinol Metab; 2010 Sep; 95(9):4345-53. PubMed ID: 20631030
[TBL] [Abstract][Full Text] [Related]
31. Gender-specific association of coronary artery calcium and lipoprotein parameters: the Heinz Nixdorf Recall Study.
Erbel R; Lehmann N; Churzidse S; Möhlenkamp S; Moebus S; Mahabadi AA; Schmermund A; Stang A; Dragano N; Grönemeyer D; Seibel R; Kälsch H; Bauer M; Bröcker-Preuss M; Mann K; Jöckel KH;
Atherosclerosis; 2013 Aug; 229(2):531-40. PubMed ID: 23701995
[TBL] [Abstract][Full Text] [Related]
32. Discordance analysis and the Gordian Knot of LDL and non-HDL cholesterol versus apoB.
Sniderman AD; Lamarche B; Contois JH; de Graaf J
Curr Opin Lipidol; 2014 Dec; 25(6):461-7. PubMed ID: 25340478
[TBL] [Abstract][Full Text] [Related]
33. Non-HDL Cholesterol or apoB: Which to Prefer as a Target for the Prevention of Atherosclerotic Cardiovascular Disease?
Langlois MR; Sniderman AD
Curr Cardiol Rep; 2020 Jun; 22(8):67. PubMed ID: 32562186
[TBL] [Abstract][Full Text] [Related]
34. Potential effects on clinical management of treatment algorithms on the basis of apolipoprotein-B/A-1 and total/high-density lipoprotein-cholesterol ratios.
Vodnala D; Bard RL; Krishnan SM; Jackson EA; Rubenfire M; Brook RD
J Clin Lipidol; 2011; 5(3):159-165. PubMed ID: 21600520
[TBL] [Abstract][Full Text] [Related]
35. Evaluating the atherogenic burden of individuals with a Friedewald-estimated low-density lipoprotein cholesterol <70 mg/dL compared with a novel low-density lipoprotein estimation method.
Whelton SP; Meeusen JW; Donato LJ; Jaffe AS; Saenger A; Sokoll LJ; Blumenthal RS; Jones SR; Martin SS
J Clin Lipidol; 2017; 11(4):1065-1072. PubMed ID: 28826567
[TBL] [Abstract][Full Text] [Related]
36. Is there a better marker of cardiovascular risk than LDL cholesterol? Apolipoproteins B and A-I--new risk factors and targets for therapy.
Walldius G; Jungner I
Nutr Metab Cardiovasc Dis; 2007 Oct; 17(8):565-71. PubMed ID: 17631989
[TBL] [Abstract][Full Text] [Related]
37. Reference intervals for six lipid analytes in 8-14 year-old school children from three different ethnical groups in the Hulun Buir area of China.
Du Y; Sun H; Li Y; Shi X; Pei D; Qi D; Wang B
Clin Lab; 2014; 60(8):1295-300. PubMed ID: 25185414
[TBL] [Abstract][Full Text] [Related]
38. Interactions of several single nucleotide polymorphisms and high body mass index on serum lipid traits.
Yin RX; Wu DF; Miao L; Htet Aung LH; Cao XL; Yan TT; Long XJ; Liu WY; Zhang L; Li M
Biofactors; 2013; 39(3):315-25. PubMed ID: 23355348
[TBL] [Abstract][Full Text] [Related]
39. Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk.
Sniderman AD; St-Pierre AC; Cantin B; Dagenais GR; Després JP; Lamarche B
Am J Cardiol; 2003 May; 91(10):1173-7. PubMed ID: 12745098
[TBL] [Abstract][Full Text] [Related]
40. Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM.
Langlois MR; Chapman MJ; Cobbaert C; Mora S; Remaley AT; Ros E; Watts GF; Borén J; Baum H; Bruckert E; Catapano A; Descamps OS; von Eckardstein A; Kamstrup PR; Kolovou G; Kronenberg F; Langsted A; Pulkki K; Rifai N; Sypniewska G; Wiklund O; Nordestgaard BG;
Clin Chem; 2018 Jul; 64(7):1006-1033. PubMed ID: 29760220
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
